LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.


Tristel Plc

0.00 (0.0%)
Share Name Share Symbol Market Type Share ISIN Share Description
Tristel Plc LSE:TSTL London Ordinary Share GB00B07RVT99 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 362.50 85,993 08:00:26
Bid Price Offer Price High Price Low Price Open Price
360.00 365.00 362.50 362.50 362.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Med, Dental, Hosp Eq-whsl 31.12 0.93 2.00 181.25 171.20
Last Trade Time Trade Type Trade Size Trade Price Currency
16:36:19 O 10,000 363.00 GBX

Tristel (TSTL) Latest News

Tristel (TSTL) Discussions and Chat

Tristel Forums and Chat

Date Time Title Posts
31/5/202316:02The TRISTEL story3,243
14/9/201814:56MRSA cleaner249
15/7/201513:01Tristel PLC: Cleaning up the sector340
03/1/201004:54tristel with charts-
13/2/200607:10TSTL with Charts & News3

Add a New Thread

Tristel (TSTL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Tristel (TSTL) Top Chat Posts

Top Posts
Posted at 20/2/2023 08:47 by metis20
Commenting on the interim results, Paul Swinney, Chief Executive of Tristel, said: "We are delighted to have increased sales by 16% on the first half of last year, above our long-term target for revenue growth.

"In all regions the level of diagnostic examinations utilising our products is significantly higher than before the commencement of the pandemic.

"We have now entered the North American market, having launched Duo Ophthalmology in Canada, and Duo Ultrasound in the USA under our EPA approval, and expect the FDA's decision on our De Novo submission in June.

"The growth prospects for the Group are stronger than ever and we look to the future with confidence."


Posted at 12/12/2022 16:28 by james188
I very much doubt that TSTL would want to be distracted from what they already have on their plate by taking over BYOT.
Posted at 12/12/2022 11:58 by piedro
What happened to the Results of the AGM:

... from Lianne Applegarth:

12 December 2022

Tristel plc
(“Tristel̶1; or the “Company”;)

Result of AGM
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

The results of the AGM will be made available on the Company's website: hxxps://

Posted at 21/11/2022 17:15 by james188
The dividend (3.93p per share) has been recommended, but not yet declared. That will happen after the AGM on 12 December 2022. It will be paid on 16 December to people who were holders as at close of business on 18 November 2022. You can find all this in the AGM notice (second resolution).
Posted at 25/10/2022 14:14 by piedro
How we have been devalued ...

................................................. 2022 ...... 2021 ... % change
Total equity (£'000) ............................ 28,987 .... 30,767 ... (5.8%)
Weighted av. diluted number of shares ('000) .... 47,769 .... 47,033 .... 1.5%
Equity per share in pence ....................... 60.68p .... 65.42p ... (7.2%)

Posted at 25/10/2022 10:40 by apad
I tend to agree with Piedro (without understanding the Partridge reference). Far too many adjustments.
On the whole transitioning and coming out of lockdown to grow internationally is not a bad story.
Change in the health sector is glacially slow at the best of times.
I'm hoping Paton will analyse the results. I don't have the skills to dig deep enough to find the flaws. My top down metrics approach doesn't frighten me however.
Pity they aren't as straightforward as BVXP (sometimes I wish that was the only share I owned 😊)

Posted at 18/7/2022 22:21 by gopher
Positive move in share price today which coincided with investor open day.Company expects 10-15% sales growth over next three years without impacting ebidta which remains at 25%. USA not in these forecasts.
Posted at 18/7/2022 12:44 by km18
Tristel (TSTL) issued a trading update for the year ended 30th June this morning. Across all the Group’s geographical markets, the number of patient procedures carried out by hospitals picked up in the second half leading to an upturn in revenue as expected. All activities in H2 were focussed on the proprietary chlorine dioxide technology in the hospital market, the Group wound down its non-core activities during H1. Revenue and adjusted profit before tax for the year from the continuing operations will be in line with consensus forecasts of £28.4m and £4.5m respectively. Management announced a 3p special dividend and there will be a final dividend of 3.93p. The business is growing again and profitable but valuation is the main cloud on the investment horizon with forward PE ratio over 40x and PS over 6x. There is a share to monitor for now...

...from WealthOracle

Posted at 01/7/2022 12:41 by piedro
TRISTEL: Pandemic-Disrupted H1 2022 Reveals Product Cull And Profit Reclassification With Dividend Held And Share Price Now 50% Lower
30 April 2022
By Maynard Paton

Posted at 23/2/2021 17:25 by james188
There are many possible reasons for the recent TSTL share price activity (including IG recently deciding to withdraw from small cap stocks), but it does not matter much to medium and long term holders.

Over time in recent years, the share price trajectory has been excellent and there is an obvious roll out strategy which is by no means solely reliant on North America. The company has barely got started in South-East Asia, has no presence in South America and is now projecting initial sales in India next month. The fact that the company remains debt free and relatively conservative are significant plusses for me. The end game may well be TSTL being acquired by a much larger fish, but why not enjoy the ride?

Tristel share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230602 22:35:11